Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition

Young Dong Yoo, Dae Hee Lee, Hyunjoo Cha-Molstad, Hyungsin Kim, Su Ran Mun, Changhoon Ji, Seong Hye Park, Ki Sa Sung, Seung Ah Choi, Joonsung Hwang, Deric M. Park, Seung Ki Kim, Kyung-Jae Park, Shin-Hyuk Kang, Sang Cheul Oh, Aaron Ciechanover, Yong J. Lee, Bo Yeon Kim, Yong Tae Kwon

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC50, 27–70 nM) compared with their differentiated controls (IC50, 47 to »100 μM). The stemness of GSCs correlates to increased ubiquitination, whose misregulation readily triggers apoptosis. PI-induced apoptosis of GSCs is independent of NF-κB but involves the phosphorylation of c-Jun N-terminal kinase as well as the transcriptional activation of endoplasmic reticulum (ER) stress-associated proapoptotic mediators. In contrast to the general notion that ER stress-associated apoptosis is signaled by prolonged unfolded protein response (UPR), GSC-selective apoptosis is instead counteracted by the UPR. ATF3 is a key mediator in GSC-selective apoptosis. Pharmaceutical uncoupling of the UPR from its downstream apoptosis sensitizes GSCs to PIs in vitro and during tumorigenesis in mice. Thus, a combinational treatment of a PI with an inhibitor of UPR-coupled apoptosis may enhance targeting of stem cells in gliomas.

Original languageEnglish
Pages (from-to)150-168
Number of pages19
JournalEMBO Reports
Volume18
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Neoplastic Stem Cells
Stem cells
Glioma
Proteasome Inhibitors
Unfolded Protein Response
Apoptosis
Endoplasmic Reticulum Stress
Stem Cells
Inhibitory Concentration 50
Proteins
Phosphorylation
JNK Mitogen-Activated Protein Kinases
Ubiquitination
Pharmaceutical Preparations
Transcriptional Activation
Neoplasms
Carcinogenesis
Chemical activation

Keywords

  • apoptosis
  • c-Jun N-terminal kinase
  • glioma stem cells
  • proteasome inhibitors
  • ubiquitin proteasome system

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Yoo, Y. D., Lee, D. H., Cha-Molstad, H., Kim, H., Mun, S. R., Ji, C., ... Kwon, Y. T. (2017). Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Reports, 18(1), 150-168. https://doi.org/10.15252/embr.201642360

Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. / Yoo, Young Dong; Lee, Dae Hee; Cha-Molstad, Hyunjoo; Kim, Hyungsin; Mun, Su Ran; Ji, Changhoon; Park, Seong Hye; Sung, Ki Sa; Choi, Seung Ah; Hwang, Joonsung; Park, Deric M.; Kim, Seung Ki; Park, Kyung-Jae; Kang, Shin-Hyuk; Oh, Sang Cheul; Ciechanover, Aaron; Lee, Yong J.; Kim, Bo Yeon; Kwon, Yong Tae.

In: EMBO Reports, Vol. 18, No. 1, 01.01.2017, p. 150-168.

Research output: Contribution to journalArticle

Yoo, YD, Lee, DH, Cha-Molstad, H, Kim, H, Mun, SR, Ji, C, Park, SH, Sung, KS, Choi, SA, Hwang, J, Park, DM, Kim, SK, Park, K-J, Kang, S-H, Oh, SC, Ciechanover, A, Lee, YJ, Kim, BY & Kwon, YT 2017, 'Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition', EMBO Reports, vol. 18, no. 1, pp. 150-168. https://doi.org/10.15252/embr.201642360
Yoo YD, Lee DH, Cha-Molstad H, Kim H, Mun SR, Ji C et al. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Reports. 2017 Jan 1;18(1):150-168. https://doi.org/10.15252/embr.201642360
Yoo, Young Dong ; Lee, Dae Hee ; Cha-Molstad, Hyunjoo ; Kim, Hyungsin ; Mun, Su Ran ; Ji, Changhoon ; Park, Seong Hye ; Sung, Ki Sa ; Choi, Seung Ah ; Hwang, Joonsung ; Park, Deric M. ; Kim, Seung Ki ; Park, Kyung-Jae ; Kang, Shin-Hyuk ; Oh, Sang Cheul ; Ciechanover, Aaron ; Lee, Yong J. ; Kim, Bo Yeon ; Kwon, Yong Tae. / Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. In: EMBO Reports. 2017 ; Vol. 18, No. 1. pp. 150-168.
@article{ec7c8233322b4a2b8ab76a699ac941f2,
title = "Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition",
abstract = "Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC50, 27–70 nM) compared with their differentiated controls (IC50, 47 to »100 μM). The stemness of GSCs correlates to increased ubiquitination, whose misregulation readily triggers apoptosis. PI-induced apoptosis of GSCs is independent of NF-κB but involves the phosphorylation of c-Jun N-terminal kinase as well as the transcriptional activation of endoplasmic reticulum (ER) stress-associated proapoptotic mediators. In contrast to the general notion that ER stress-associated apoptosis is signaled by prolonged unfolded protein response (UPR), GSC-selective apoptosis is instead counteracted by the UPR. ATF3 is a key mediator in GSC-selective apoptosis. Pharmaceutical uncoupling of the UPR from its downstream apoptosis sensitizes GSCs to PIs in vitro and during tumorigenesis in mice. Thus, a combinational treatment of a PI with an inhibitor of UPR-coupled apoptosis may enhance targeting of stem cells in gliomas.",
keywords = "apoptosis, c-Jun N-terminal kinase, glioma stem cells, proteasome inhibitors, ubiquitin proteasome system",
author = "Yoo, {Young Dong} and Lee, {Dae Hee} and Hyunjoo Cha-Molstad and Hyungsin Kim and Mun, {Su Ran} and Changhoon Ji and Park, {Seong Hye} and Sung, {Ki Sa} and Choi, {Seung Ah} and Joonsung Hwang and Park, {Deric M.} and Kim, {Seung Ki} and Kyung-Jae Park and Shin-Hyuk Kang and Oh, {Sang Cheul} and Aaron Ciechanover and Lee, {Yong J.} and Kim, {Bo Yeon} and Kwon, {Yong Tae}",
year = "2017",
month = "1",
day = "1",
doi = "10.15252/embr.201642360",
language = "English",
volume = "18",
pages = "150--168",
journal = "EMBO Reports",
issn = "1469-221X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition

AU - Yoo, Young Dong

AU - Lee, Dae Hee

AU - Cha-Molstad, Hyunjoo

AU - Kim, Hyungsin

AU - Mun, Su Ran

AU - Ji, Changhoon

AU - Park, Seong Hye

AU - Sung, Ki Sa

AU - Choi, Seung Ah

AU - Hwang, Joonsung

AU - Park, Deric M.

AU - Kim, Seung Ki

AU - Park, Kyung-Jae

AU - Kang, Shin-Hyuk

AU - Oh, Sang Cheul

AU - Ciechanover, Aaron

AU - Lee, Yong J.

AU - Kim, Bo Yeon

AU - Kwon, Yong Tae

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC50, 27–70 nM) compared with their differentiated controls (IC50, 47 to »100 μM). The stemness of GSCs correlates to increased ubiquitination, whose misregulation readily triggers apoptosis. PI-induced apoptosis of GSCs is independent of NF-κB but involves the phosphorylation of c-Jun N-terminal kinase as well as the transcriptional activation of endoplasmic reticulum (ER) stress-associated proapoptotic mediators. In contrast to the general notion that ER stress-associated apoptosis is signaled by prolonged unfolded protein response (UPR), GSC-selective apoptosis is instead counteracted by the UPR. ATF3 is a key mediator in GSC-selective apoptosis. Pharmaceutical uncoupling of the UPR from its downstream apoptosis sensitizes GSCs to PIs in vitro and during tumorigenesis in mice. Thus, a combinational treatment of a PI with an inhibitor of UPR-coupled apoptosis may enhance targeting of stem cells in gliomas.

AB - Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC50, 27–70 nM) compared with their differentiated controls (IC50, 47 to »100 μM). The stemness of GSCs correlates to increased ubiquitination, whose misregulation readily triggers apoptosis. PI-induced apoptosis of GSCs is independent of NF-κB but involves the phosphorylation of c-Jun N-terminal kinase as well as the transcriptional activation of endoplasmic reticulum (ER) stress-associated proapoptotic mediators. In contrast to the general notion that ER stress-associated apoptosis is signaled by prolonged unfolded protein response (UPR), GSC-selective apoptosis is instead counteracted by the UPR. ATF3 is a key mediator in GSC-selective apoptosis. Pharmaceutical uncoupling of the UPR from its downstream apoptosis sensitizes GSCs to PIs in vitro and during tumorigenesis in mice. Thus, a combinational treatment of a PI with an inhibitor of UPR-coupled apoptosis may enhance targeting of stem cells in gliomas.

KW - apoptosis

KW - c-Jun N-terminal kinase

KW - glioma stem cells

KW - proteasome inhibitors

KW - ubiquitin proteasome system

UR - http://www.scopus.com/inward/record.url?scp=85006983243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006983243&partnerID=8YFLogxK

U2 - 10.15252/embr.201642360

DO - 10.15252/embr.201642360

M3 - Article

C2 - 27993939

AN - SCOPUS:85006983243

VL - 18

SP - 150

EP - 168

JO - EMBO Reports

JF - EMBO Reports

SN - 1469-221X

IS - 1

ER -